Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Athersys, Inc. (ATHX)

0.2861   0.024 (9.16%) 06-29 17:56
Open: 0.2611 Pre. Close: 0.2621
High: 0.3293 Low: 0.2611
Volume: 9,743,574 Market Cap: 74(M)
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.33 - 0.33 0.33 - 0.33
Low: 0.26 - 0.26 0.26 - 0.26
Close: 0.28 - 0.29 0.29 - 0.29

Technical analysis

as of: 2022-06-29 4:51:34 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.38     One year: 0.49
Support: Support1: 0.18    Support2: 0.14
Resistance: Resistance1: 0.32    Resistance2: 0.41
Pivot: 0.3
Moving Average: MA(5): 0.26     MA(20): 0.3
MA(100): 0.57     MA(250): 0.98
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 21.6     %D(3): 19.2
RSI: RSI(14): 44.7
52-week: High: 1.8  Low: 0.18
Average Vol(K): 3-Month: 8,082 (K)  10-Days: 15,651 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ATHX ] has closed above bottom band by 39.6%. Bollinger Bands are 39.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 24 Jun 2022
StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX) - Defense World

Sun, 19 Jun 2022
Shareholders in Athersys (NASDAQ:ATHX) have lost 84%, as stock drops 20% this past week - Simply Wall St

Thu, 09 Jun 2022
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday - InvestorPlace

Thu, 09 Jun 2022
Investment Analysts' Downgrades for June 8th (ATHX, ATNM, AVO, AVPT, BLZE, BNTC, BOWL, BSIG, CABA, CCNE) - Defense World

Thu, 09 Jun 2022
ATHX stock falls over proposal for reverse stock split (NASDAQ:ATHX) - Seeking Alpha

Wed, 08 Jun 2022
Athersys Hosting KOL Panel Event to Discuss TREASURE Data - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 235 (M)
% Held by Insiders 2.2458e+008 (%)
% Held by Institutions 7.6 (%)
Shares Short 23,460 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -8.563e+007
EPS Est Next Qtl -0.08
EPS Est This Year -0.24
EPS Est Next Year -0.31
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 569.7
Return on Equity (ttm) -90.3
Qtrly Rev. Growth 5.51e+006
Gross Profit (p.s.) -0.27
Sales Per Share 0.02
EBITDA (p.s.) -0.37
Qtrly Earnings Growth -0.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -76 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 11.1
Price to Cash Flow -3.72

Stock Dividends

Dividend 0
Forward Dividend 2.562e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.